International Journal of Emergency Medicine volume 14, Article number: 44 (2021)
To the Editor,
After reading the review article titled “The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review” by Kevin Takakuwa and Raquel Schears published in the International Journal of Emergency Medicine (2021 Feb 10;14(1):10), we want to first congratulate the authors for the successful publication of this article. Additionally, we hope to contribute some of our findings to further enhance this line of research.
As the legalization of cannabis continues to spread in North America, it has become increasingly important for physicians to recognize and treat cannabinoid-related syndromes. In this secondary analysis of a randomized controlled trial that studied the effect of topical capsaicin on patients presenting to the emergency department (ED) with cannabinoid hyperemesis syndrome (CHS), we describe symptomatology and return visits in patients suffering from CHS [1].
Our study population consisted of 29 participants with a mean age of 30 years. Most patients were Black (90%) and hypertension was the most frequent comorbid condition (28%). All participants experienced nausea and vomiting. Other reported symptoms included abdominal pain (90%), chills (52%), and diarrhea (27%). Abdominal pain was mild (mean visual analog scale (VAS) 2.7 ± 1.2 cm) compared to nausea (mean VAS 7.3 ±2.5 cm). Sixteen patients accounted for 41 repeat ED visits and 10 hospitalizations for CHS-related symptoms within 6 months.
Data indicates that the increased accessibility of cannabis in the USA is associated with an increase in cannabis-related conditions presenting to the ED [2]. Many of these conditions have only recently been characterized and a clearer understanding of CHS symptomatology may improve its accurate recognition and treatment.
While the majority of published studies of CHS obtain retrospective data or present small case series, this prospective data provides an accurate assessment of patient symptoms and high rates of return visits. It also includes data on a largely Black cohort, whereas most published literature on CHS is inclusive of White patients. We present quantified data on the degree of nausea common among CHS patients and the degree of abdominal pain. Contrary to prior studies, we found that abdominal pain severity is overall mild to moderate, especially when compared to nausea severity [3]. Given these findings, a focus on antiemetic treatment rather than analgesics appears warranted in the initial management of these patients.
In this cohort of CHS patients, it was found that nausea was a larger concern for patients than abdominal pain and that repeat encounters for related symptoms were common. As cannabinoid use becomes more mainstream, physicians in all settings should include CHS in their differential when faced with GI symptoms.
Data is not publically available
Cannabinoid hyperemesis syndrome
Visual analog scale
Cyclic vomiting syndrome
Dean DJ, Sabagha N, Rose K, Weiss A, France J, Asmar T, et al. A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome. Acad Emerg Med. 2020;27(11):1166–72. https://doi.org/10.1111/acem.14062.
Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med. 2019 Apr 16;170(8):531–7. https://doi.org/10.7326/M18-2809.
Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114–9. https://doi.org/10.1016/j.mayocp.2011.10.005.
We would like to thank the Department of Emergency Medicine at Henry Ford Hospital for supporting this research.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
All authors were involved in writing and manuscript editing. JM and PM conceived the design. JM performed analysis. The authors read and approved the final manuscript.
The study was approved by the institutional review board and all participants provided written consent.
Not applicable
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Ma, P.H., Joyce, K.M., Morton, T. et al. A focused, longitudinal analysis of cannabinoid hyperemesis syndrome symptomatology. Int J Emerg Med 14, 44 (2021). https://doi.org/10.1186/s12245-021-00367-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12245-021-00367-4
